Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Centre, shared a post on X:
“Deep, multi-omic analysis of adjuvant atezolizumab for ccRCC by Sumanta K. Pal and team building on prior KIM-1 studies.
One take away is KIM-1 high, Teff high has longer DFS with atezo than placebo.”
Andy Hahn highlighted new findings from Sumanta K. Pal’s team, showing that patients with high KIM-1 and Teff expression experienced longer disease-free survival when treated with atezolizumab in adjuvant clear cell renal cell carcinoma.
More posts featuring Andy Hahn.
